# Carmine Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carmine-therapeutics

- Industry: Biotechnology
- Headquarters: Singapore
- Website: www.carminetherapeutics.com
- Latest round: Series A (Oct 13, 2022)
- Investors on record: 4

## About

Based in Singapore, and established in 2019, Carmine Therapeutics is a biotechnology company that focuses on R&D of the red cell extracellular vesicles genetic therapeutics. It was founded in 2019 by EVX Ventures, Professors Harvey Lodish, Minh Le and Jiahai Shi. Professor Lodish, is also one of the founder members of several successful biotech companies, such as Genzyme and Millennium Pharmaceuticals. In 2020, it aligned with Takeda Pharmaceuticals to develop non-viral gene therapies for 2 targets.  

Carmine Therapeutics is developing gene therapeutics, based on the red cell extracellular vesicles, which can overcome the difficulties of viral-based gene therapies for immunogenicity, and small transgene capacity, and manufacturing.

## Funding rounds

- Series A, Oct 13, 2022 — Simcere Pharmaceutical Group Limited, Cystic Fibrosis Foundation, Huagai Capital, EVX Ventures

## Investors

- Simcere Pharmaceutical Group Limited — Series A
- Cystic Fibrosis Foundation — Series A
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- EVX Ventures (https://capitalatlas.ai/funds/evx-ventures) — Series A